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Serum Soluble Triggering Receptor Expressed 
on Myeloid Cells-1 in Acute Respiratory Distress
Syndrome: A Prospective Observational Cohort Study
Ming-Tzer Lin,1 Yu-Feng Wei,2 Shih-Chi Ku,3 Chih-An Lin,4 Chao-Chi Ho,3* Chong-Jen Yu3
Background/Purpose: Serum soluble triggering receptor expressed on myeloid cells-1 (sTREM-1), a detec-
tor of acute inflammatory response to microbial products and a good marker for diagnosing sepsis and
pneumonia, has not yet been described as a predictor for infection or a prognostic factor in patients with
acute respiratory distress syndrome (ARDS).
Methods: This prospective observational cohort study enrolled 63 ventilated adult patients with ARDS; 
50 as septic and 13 as non-septic, and followed them for 28 days in intensive care units at a university hos-
pital in Taiwan. Serial serum sTREM-1 levels and cytokines, such as interleukin (IL)-1, IL-8, and tumor
necrosis factor-α, on days 1, 3, 5, 7 and 14 were measured by an enzyme-linked immunosorbent assay.
The association between biomarkers and clinical infectious diagnosis/outcome in ARDS was explored.
Results: Serum sTREM-1 and cytokine levels could not differentiate septic from non-septic ARDS. Serum
log sTREM-1 and inflammatory cytokine levels were correlated positively (r = 0.325 for IL-1β; r = 0.247 for
IL-8; r = 0.480 for tumor necrosis factor-α). As prognostic factors, higher serum sTREM-1 level on day 1
and increasing levels over time, especially in the first 5 days, were independent predictors of mortality on
day 28, using a multivariate Cox regression model. Serum sTREM-1 levels remained stable or even 
increased in the non-surviving patients, but decreased in the survivors.
Conclusion: Serum sTREM-1 level might not be a reliable marker for infection in ARDS patients. However,
as an inflammatory marker, initial serum sTREM-1 level and its trend over time, especially in the first 5 days,
could be predictive of short-term mortality. A progressive decline in serum sTREM-1 levels during follow-
up indicates a favorable outcome, whereas persistently elevated sTREM-1 indicates a poor prognosis and
should lead to a re-evaluation of therapy.
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Acute respiratory distress syndrome (ARDS) is a
devastating clinical condition with high morbid-
ity and mortality, and can have a septic or non-
septic etiology.1 Sepsis is the most common cause
and has a worse prognosis compared to other
risk factors.2,3 The discrimination between septic
and non-septic causes of ARDS is important, be-
cause it can prompt physicians to start multi-
modal treatment of severe sepsis, including the
use of recombinant human activated protein C
(drotrecogin-α), as early as possible.4,5 It can also
encourage them to feel free to use corticosteroid
therapy in the fibroproliferative phase of ARDS
without an ongoing infectious process.6 However,
prompt and correct diagnosis of septic ARDS is
difficult because many infectious clinical features,
such as changes in body temperature, leukocyto-
sis, or tachycardia, are non-specific. A serum bio-
logical marker that indicates severe bacterial
infection would be useful in this situation. Many
inflammatory biomarkers have been studied to
differentiate septic from non-septic ARDS, but
only a few fulfill the requirements.7–10
Trigger receptor expressed on myeloid cells-1
(TREM-1) has recently been identified as an in-
fectious marker.11,12 TREM-1 is a transmembrane
glycoprotein that consists of a single extracellular
immunoglobulin-like domain, a transmembrane
region, and a short cytoplasmic tail.11,13 TREM-1
is a receptor that is expressed on neutrophils and
macrophages/monocytes, which are the main ef-
fector cells in innate responses.11,13 TREM-1 can
trigger and amplify the inflammatory response. In
the presence of Gram-positive and Gram-negative
bacteria, as well as fungi, the expression of TREM-1
is greatly upregulated on neutrophils and mono-
cytes, but TREM-1 is hardly expressed at all in
non-infectious inflammatory diseases, such as
psoriasis, ulcerative colitis, vasculitis, and granu-
lomatous disorders.14 Soluble TREM-1 (sTREM-1)
does not have the transmembrane and intracellu-
lar domains that are released from activated phago-
cytes, and can be found in body fluids.15–18 In
previous studies, the presence of sTREM-1 in the
bronchoalveolar fluid has been shown to be a
good indicator of lung infection.16,18 In addition,
serum sTREM-1 has been shown to be able to dis-
tinguish survivors from non-survivors of sepsis.17
However, information on the diagnostic role of
sTREM-1 as an infectious marker in ARDS patients
has been lacking until now.
Therefore, we designed a clinical observational
study to investigate whether this new inflamma-
tory marker, sTREM-1, can differentiate septic from
non-septic ARDS. In addition, we investigated the
serial changes of sTREM-1, as well as serum cy-
tokine levels such as IL (interleukin)-1, IL-8, and
tumor necrosis factor (TNF)-α in ARDS patients
and their association with clinical outcomes.
Materials and Methods
Study subjects
All ventilated patients admitted to the intensive
care units (ICUs) of the National Taiwan University
Hospital between October 2007 and March 2008
were surveyed. We enrolled patients who fulfilled
the clinical diagnosis for ARDS, as defined by the
established recommendations of the American–
European Consensus Conference Committee in
199419 (i.e. acute onset; bilateral infiltrates on chest
radiography; PaO2/FiO2 ratio ≤ 200; pulmonary-
arterial wedge pressure ≤ 18 mmHg or absence 
of clinical evidence of left-atrial hypertension; and
predisposing conditions associated with the de-
velopment of ARDS).
Patients were excluded if they were <18 years of
age, pregnant, treated with corticosteroids > 1 mg/
kg equivalent prednisolone, or bone marrow/
organ transplant recipients; or if neutropenia
(absolute neutrophil count < 500/μL) or acquired
immune deficiency syndrome were noted. The
study was approved by the National Taiwan Uni-
versity Hospital institutional review board, and
informed consent from all of the patients or their
relatives was obtained before enrollment.
Study design
Upon enrollment, demographic and laboratory
characteristics were collected and are presented in
Table 1. All patients were followed until discharge
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Table 1. Demographic and laboratory characteristics on enrollment of acute respiratory distress syndrome
patients
Characteristics* Septic (n = 50)
Pathogen-confirmed 
Non-septic (n = 13)
septic (n = 34)
Age (yr) 75 (57–83) 76 (55–83) 62 (48–67)†‡
Sex, male 30 (60) 22 (65) 8 (62)
History of gouty arthritis 4 (8) 2 (6) 2 (15)
Recent abdominal surgery 6 (12) 5 (15) 0 (0)
Malignancy 17 (34) 10 (29) 7 (54)
Shock 32 (64) 23 (68) 8 (62)
Positive blood cultures 12 (24) 12 (35) 0 (0)†‡
Duration of SIRS before enrollment (d) 2 (1–6.5) 2 (1–5) 3 (1–5)
Etiology of ARDS
Infectious focus 50 34
Pneumonia 44 28
Urosepsis 2 2
Liver abscess 1 1
Biliary tract infection 1 1
Endocarditis 1 1
Necrotizing fasciitis 1 1
Drug-related acute lung injury 3
TRALI 2
Lymphoma with lung involvement 2
Catastrophic APS 1
Vasculitic pulmonary hemorrhage 1
Pancreatitis 1
Chest contusion 1
Blood aspiration§ 1
Inhalation injury 1
Laboratory data
Body temperature (°C) 37.8 (36.9–38.2) 37.8 (37.0–38.3) 37.9 (36.4–38.8)
WBC (/μL) 10,990 (4095–15,535) 8515 (2363–13,663) 13,270 (6045–21,730)
ANC (/μL) 8711 (2419–12,566) 6398 (1478–12,212) 11,153 (5514–15,221)
CRP (mg/dL) 12.2 (6.87–19.68) 12.2 (7.35–19.47) 6.88 (1.95–16.66)†
Biomarker
Log (serum sTREM-1, pg/mL) 1.29 (0–2.31) 0.87 (0–2.22) 2.01 (0–2.87)
Log (serum IL-1β, pg/mL) 0.33 (0–1.23) 0.61 (0–1.38) 0.52 (0.04–1.05)
Log (serum IL-8, pg/mL) 2.43 (2.27–2.97) 2.67 (2.28–2.98) 2.33 (2.07–2.58)
Log (serum TNF-α, pg/mL) 0.82 (0–1.70) 1.03 (0–1.76) 0.90 (0.18–1.26)
*Data presented as medians (interquartile range) or n (%); †p ≤ 0.05 between septic and non-septic groups; ‡p ≤ 0.05 between
pathogen-confirmed septic and non-septic groups; §aspiration of blood into the lung tissue secondary to upper airway bleeding.
ARDS = acute respiratory distress syndrome; SIRS = systemic inflammatory response syndrome; TRALI = transfusion-related acute lung
injury; APS = antiphospholipid syndrome; WBC = white blood cell count; ANC = absolute neutrophil count; CRP = C-reactive protein;
sTREM-1 = soluble triggering receptor expressed on myeloid cells-1; IL = interleukin; TNF = tumor necrosis factor.
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or death. The length of ICU stay and outcome of
the 28-day period were also recorded.
Septic or non-septic etiology was retrospec-
tively determined according to the decisions of
the clinical attending physicians and the defini-
tion of the American College of Chest Physicians/
Society of Critical Care Medicine Consensus
Conference Committee.20 The septic group was
based on a presumed or identified source of in-
fection, in combination with signs of systemic
inflammatory response syndrome (SIRS). Within
the septic group, patients with causative micro-
bial pathogens were defined as the pathogen-
confirmed septic group. Patients in the non-septic
group only had SIRS without a searchable infec-
tious focus. All patients were managed according
to the Surviving Sepsis Campaign Guidelines.21 The
symptoms of SIRS were as defined previously20
and the duration of SIRS before enrollment was
recorded. Causative pathogens were defined as:
organisms cultured or grown in a normally ster-
ile body fluid or tissue; intracellular organisms
phagocytosed by the polymorphonuclear cells,
as seen by microscopic examination of sputum
specimens; or urine Streptococcus pneumoniae anti-
gen or virus (using the polymerase chain reaction
for detection of herpes simplex virus DNA) by
serological analysis.
Measurement of sTREM-1 and 
inflammatory cytokines
The levels of sTREM-1 were measured using an
enzyme-linked immunosorbent assay (ELISA;
R&D Systems, Minneapolis, MN, USA). IL-1β, IL-
8 and TNF-α in the serum were determined using
cytokine-specific ELISAs according to the manu-
facturer’s protocol (R&D Systems). All mea-
surements were performed in duplicate, as in our
previous study.22 Serum levels of high-sensitivity
C-reactive protein (CRP) were measured with 
a latex-particle-enhanced immunoturbidimetric
assay.
Serum sTREM-1 and cytokine levels on days
1, 3, 5, 7 and 14 were measured. “ARDS Day 1” was
defined as the day that the patient fulfilled the
ARDS criteria: the day of enrollment. The clinical
attending physicians or members of the primary
care team were blinded to these data. For non-
surviving patients, serum sTREM-1 and cytokines
levels were followed until death.
Statistical analysis
Descriptive results of continuous variables were ex-
pressed as medians (interquartile ranges). sTREM-1
and cytokines levels were transformed to log val-
ues. Variables were tested for comparison between
the different groups using the Pearson χ2 test/
Fisher’s exact test for categorical data and the
non-parametric test, the Mann–Whitney U test,
for numerical data. Statistical correlations were
calculated with Spearman’s non-parametric coef-
ficient (r). To adjust for baseline differences, we
used a univariate general linear model and set
age and lung injury score (LIS) as covariates.
Possible confounding factors on elevation of serum
sTREM-1 were analyzed with multivariate logis-
tic regression to clarify the effect of the septic eti-
ology. A survival analysis was performed using
the Kaplan–Meier method and the log-rank test.
Multivariate analyses were performed using the
Cox proportional-hazards regression model for
28-day mortality, with a 95% confidence interval
(CI). To enter this model, continuous variables
were transformed into a categorical binary value
using median values, and the trend for sTREM-1 or
cytokines over time was represented by the slope
of the regression line over multiple time points.
All analyses were done with SPSS version 13.0
(SPSS, Chicago, IL, USA). A p value <0.05 for signif-
icance and two-tailed tests was used in this study.
Results
Characteristics of the study population
In this prospective study, 1098 patients who were
admitted to the medical/burns/surgical ICUs were
surveyed over 6 months. Sixty-three ARDS patients
who fulfilled the inclusion criteria were enrolled.
The etiology was septic in 50 (79%) patients and
non-septic in 13 (21%). Infections were micro-
biologically proven in 34 of 50 (68%) septic 
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patients. The baseline characteristics of the study
groups are shown in Table 1.
Between the septic or pathogen-confirmed sep-
tic and non-septic groups, age and LIS scores were
significantly different. The CRP level was signifi-
cantly higher in the septic group (p = 0.047), but
this showed only an increasing trend between the
pathogen-confirmed septic and non-septic groups
(p = 0.057).
Diagnostic value of baseline sTREM-1 and
inflammatory cytokines assay for sepsis
At enrollment, no difference was observed in the
serum log sTREM-1 levels between the septic and
non-septic groups (p = 0.501); the same was true
of the serum log cytokine levels (Table 1). After
adjusting the baseline for age, LIS, and duration
of SIRS before enrollment, there was still no sig-
nificant difference in serum log sTREM-1 values
between the septic and non-septic groups (p =
0.896). Among patients whose duration of SIRS
before enrollment was < 48 hours, serum log
sTREM-1 level did not differ between the 24 pa-
tients in the septic group and the nine in the
non-septic group (p = 0.564). No correlation was
noted between serum log sTREM-1 levels at en-
rollment and the initial PAO2/FiO2 ratio, absolute
neutrophil count, or CRP level, except for the log
IL-1 (r = 0.343, p = 0.008) and TNF-α (r = 0.422,
p=0.001). In the pathogen-confirmed septic group,
sTREM-1 was elevated especially in Gram-negative
pathogens (Figure 1), but no statistical significance
was observed.
Using multivariate logistic regression models
to adjust for possible confounding factors, in-
cluding history of gouty arthritis, malignancy,
abdominal surgery in the past 3 months, pres-
ence of pancreatitis, LIS, duration of SIRS before
enrollment, and age, septic etiology for ARDS
was not found to be an independent factor for 
elevation of the serum log sTREM-1 value (95%
CI = −1.103 to 0.784, p = 0.736).
Severity of ARDS and outcome
Overall, 27 patients with ARDS died before day
28 and the mortality rate was 42.9%, which is
concurrent with the predictive risk of death based
on the Acute Physiology and Chronic Health Eval-
uation (APACHE) II and Sequential Organ Failure
Assessment (SOFA) scores (mean ± standard de-
viation: 25.33±7.87 and 9.87±3.82, respectively).
Clinical and laboratory data of survivors and
non-survivors are listed in Table 2. Non-survivors
were younger and had longer drinking histories
(30%) than the survivors (5%) (p = 0.01). Survival
analysis showed that a younger age, a history of
chronic liver disease, and higher baseline severity
scores (SOFA and APACHE II) were associated
with a higher mortality rate. Sepsis and multiple
organ failure were the most common causes of
short-term mortality (71%), and only 6% died
because of respiratory failure.
Prognostic value of sTREM-1 and
inflammatory cytokines assay
In univariate analysis, serum log sTREM-1 levels
on day 1 could not be used as a prognostic factor
for mortality on day 28 (p = 0.394), nor could log
cytokine levels be used (Table 2). Higher serum
CRP levels, however, were noted in non-survivors
(p = 0.007).
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Figure 1. Serum level of soluble triggering receptor expressed
on myeloid cells-1 in the different causative pathogens of
septic acute respiratory distress syndrome. GNB = Gram-
negative bacilli; GPC = Gram-positive cocci.
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Serum log sTREM-1 level was positively cor-
related with log IL-1β (r = 0.325, p ≤ 0.001), log
IL-8 (r = 0.247, p ≤ 0.001), and log TNF-α levels
(r = 0.480, p ≤ 0.001). To analyze duration of the
course, 95% CI of the mean values for serum log
sTREM-1 over time were plotted in Figure 2. In
non-survivors, baseline serum log sTREM-1 level
was higher and there was a trend to increase over
time, especially over the first 5 days. The slope 
of the regression line for multiple time points
confirmed this phenomenon in the serum log
sTREM-1 level (p = 0.005, Table 2).
In the multivariate Cox regression model, age
≤ 65 years (p = 0.003), presence of chronic liver
disease (p = 0.016), higher baseline APACHE II
score (p < 0.001), and higher initial SOFA score
(p = 0.017) remained independent factors for the
prediction of mortality on day 28 (Table 3). With
regard to sTREM-1 and cytokines, only day 1 serum
log sTREM-1 levels (p = 0.008), and a progressive
increase over time in serum log sTREM-1 levels
(p = 0.040) and log IL-1β levels (p = 0.004) were
independent factors.
Discussion
Serum sTREM-1 is one of the most promising pa-
rameters for differentiating sepsis from other SIRS,
according to previous studies.15,23 However, in our
study, serum sTREM-1 levels on day 1 of ARDS
could not differentiate septic from non-septic
Table 2. Clinical and laboratory data according to outcome
Characteristics*†
28-day outcome
Survival (n = 36) Non-survival (n = 27) p‡
Sex, male 25 (69) 13 (48) 0.120
Age > 65 yr 25 (69) 9 (41) 0.016§
Chronic liver disease 1 (3) 3 (11) 0.024§
Septic etiology 30 (83) 20 (74) 0.525
APACHE II score 22.5 (18.5–26.8) 28 (23–34) 0.001§
SOFA score at enrollment 9 (7–11) 13 (8–14) 0.004§
LIS 2.75 (2.25–3.25) 3 (2.75–3.75) 0.545
Length of ICU stay (d) 17 (12–22) 8 (4–15) < 0.001§
CRP (mg/dL) 7.33 (2.87–14.37) 13.91 (8.96–19.97) 0.004§
Serum sTREM-1 (pg/mL)
Log D1 0.47 (0–2.29) 1.99 (0–2.58) 0.388
Log Dfirst to Log Dleast slope ≥ 0 15 (42) 20 (74) 0.005§
Serum IL-1β (pg/mL)
Log D1 0.31 (0–1.20) 0.43 (0–1.12) 0.502
Log Dfirst to Log Dleast slope ≥ 0 14 (58) 15 (56) 0.187
Serum IL-8 (pg/mL)
Log D1 2.34 (2.09–2.85) 2.55 (2.28–2.92) 0.142
Log Dfirst to Log Dleast slope ≥ 0 15 (42) 16 (59) 0.179
Serum TNF-α (pg/mL)
Log D1 0.82 (0–1.58) 0.94 (0–1.61) 0.403
Log Dfirst to Log Dleast slope ≥ 0 15 (42) 13 (48) 0.598
*Data presented as n (%) or medians (interquartile range); †continuous variables were transferred to a categorical binary using the 
median value; ‡comparison using the Kaplan–Meier product-limit method and the statistical significance was assessed by a log-rank
test; §p ≤ 0.05. APACHE = Acute Physiology and Chronic Health Evaluation; SOFA = Sequential Organ Failure Assessment; LIS = Lung
Injury Score; ICU = intensive care unit; CRP = C-reactive protein; sTREM-1 = soluble triggering receptor expressed on myeloid cells-1;
IL = interleukin; TNF = tumor necrosis factor.
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groups of critically ill patients. Univariate or mul-
tivariate analysis, after adjusting for possible con-
founding factors, such as recent major abdominal
surgery,24 pancreatitis,25 active malignancy,22,26
or gouty arthritis,27 showed that septic etiology of
ARDS was not associated with elevation of serum
log sTREM-1 level. Moreover, considering the du-
ration of SIRS in septic or non-septic groups be-
fore the onset of ARDS, it did not seem to affect
the serum log sTREM-1 levels according to the
univariate, multivariate, or subgroup analyses for
patients whose duration of SIRS before enroll-
ment was <48 hours. These results depart from the
findings for sepsis reported by Gibot et al.15,17,23
This could be explained as follows. First, ARDS
induced by direct lung injury might have a higher
sTREM-1 concentration in the lungs than in the
serum.18,28 Pulmonary infection or aspiration-
related ARDS might have lower sTREM-1 levels
in the serum, although they are classified as septic
ARDS. Second, recent clinical studies investigat-
ing the role of sTREM-1 in an infectious diagnosis
have shown that sTREM-1 is not a good marker
for infection in sepsis29 or ventilator-associated
pneumonia30,31 in critically ill patients. To explain
these discrepancies, some have proposed the fol-
lowing: different sensitivities of the sTREM-1 assays
(ELISA or immunoblotting),31 exposure to antibi-
otics or lack thereof,18,31 inadequate controls in the
absence of suspected infection,30 and differences
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Figure 2. Time course of log value of the serum level of
soluble triggering receptor expressed on myeloid cells-1 in
surviving and non-surviving patients. Data expressed as
means with 95% confidence interval. The number of avail-
able cases is listed below and decreases over time for non-
survival. CI = confidence interval.
Table 3. Cox regression analysis of baseline and sequential variables in acute respiratory distress syndrome
patients for 28-day mortality
Variable* Univariate HR (95% CI) Multivariate HR (95% CI)
Age > 65 yr 0.404 (0.187–0.872)† 0.132 (0.035–0.495)†
Presence of chronic liver disease 3.655 (1.089–12.270)† 0.116 (0.02–0.665)†
LIS 1.265 (0.586–2.727) 1.085 (0.338–3.490)
SOFA score 2.958 (1.348–6.487)† 7.700 (1.444–41.047)†
APACHE II score 3.632 (1.654–7.977)† 18.986 (4.088–88.185)†
CRP, day 1 3.173 (1.372–7.336)† 2.316 (0.652–8.226)
Log sTREM-1, day 1 1.392 (0.651–2.975) 6.338 (1.607–24.998)†
Log IL-1β, day 1 1.299 (0.600–2.811) 1.355 (0.357–5.140)
Log IL-8, day 1 1.788 (0.810–3.945) 0.935 (0.280–3.114)
Log TNF-α, day 1 1.385 (0.640–2.995) 3.691 (0.668–20.998)
Log sTREM-1 trend (slope ≥ 0) 3.160 (1.333–7.490)† 3.893 (1.062–14.269)†
Log IL-1β trend (slope ≥ 0) 1.652 (0.773–3.532) 7.076 (1.877–26.679)†
Log IL-8 trend (slope ≥ 0) 1.677 (0.778–3.617) 1.586 (0.451–5.574)
Log TNF-α trend (slope ≥ 0) 1.223 (0.575–2.602) 2.723 (0.444–16.710)
*Continuous variables were transferred to a categorical binary using the median value; †p ≤ 0.05. HR = hazard ratio; CI = confidence 
interval; LIS = Lung Injury Score; SOFA = Sequential Organ Failure Assessment; APACHE = Acute Physiology and Chronic Health
Evaluation; CRP = C-reactive protein; sTREM-1 = soluble triggering receptor expressed on myeloid cells-1; IL = interleukin; TNF = tumor
necrosis factor.
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among patient groups in various studies.31 Third,
limited case numbers and a retrospective defini-
tion of non-septic ARDS might compromise the
diagnostic value of sTREM-1 for infection.
Although serum sTREM-1 might not be suitable
as an infectious marker in ARDS, we still noted
that, in pathogen-confirmed septic ARDS pa-
tients, serum sTREM-1 was higher when cultures
grew Gram-negative bacilli such as Pseudomonas
aeruginosa, Klebsiella pneumoniae, and Escherichia
coli. In patients with Gram-positive coccal, fungal,
or viral infections, serum sTREM-1 levels were
lower. However, there was no significant differ-
ence between them.
Instead of serum sTREM-1 levels as an infec-
tious marker, our findings suggest that sTREM-1
is a prognostic factor. In multivariate analysis, a
higher serum log sTREM-1 level at day 1 and an
increased trend of serum log sTREM-1 levels over
time, especially in the first 5 days, were associated
with an unfavorable outcome. In comparison to
sTREM-1 levels in septic patients, our findings are
in line with those of Gibot et al32 and Determann
et al,18 which showed a progressive decline of
serum sTREM-1 in surviving patients, especially
in the first 5 days.
Furthermore, our results showed a significant
positive correlation between serum log sTREM-1
and inflammatory cytokine levels (IL-1β, IL-8
and TNF-α). From the above-mentioned results,
elevated serum sTREM-1 levels in ARDS patients
indicated severe inflammation, which was what
induced the higher mortality rate, and not the 
infection. The first 5 days of serum sTREM-1 ele-
vation in ARDS is compatible with the acute ex-
udative phase when alveolar macrophages and
neutrophils are recruited in the alveolar space,
and most cytokines are released.33 Our prognostic
findings in ARDS patients were similar to those
in the sepsis study of Gibot et al.32 Further inter-
vention was needed for the elevation of serum
log sTREM-1 levels, especially during the first 
5 days of follow-up, which indicated the progres-
sion of a systemic inflammatory response. Such
data clarified that sTREM-1 was an inflammatory
marker, albeit not a good infectious one.
Our findings confirmed that higher SOFA and
APACHE II scores were associated with poor prog-
nosis, as did the results of previous studies.34
However, age < 65 years in our study was another
prognostic factor with unfavorable outcomes. This
might have been due to a longer drinking history
in our younger patients; alcohol abuse is thought
to be associated with high mortality in ARDS 
patients, according to the study of Wakabayashi
et al.35 In addition, a persistent or elevated trend
of serum IL-1β might have predicted poor prog-
nosis in our multivariate analysis (Table 3), which
was also found in the previous ARDS study of
Goodman et al.7
With regard to serum CRP level in our study,
it might be used to differentiate septic and non-
septic ARDS patients, even better than serum
sTREM-1. Barati et al reported the same phe-
nomenon as we have: CRP performs better than
sTREM-1 in diagnosing infection.36 Barati et al,
however, noted that the diagnostic accuracy of
sepsis markers is highly dependent on the setting
in which they are tested. Their study was con-
ducted in a heterogeneous group of ICU patients,
which was similar to our ARDS group, that con-
sisted of various causative etiologies. The heteroge-
nous population and small number of patients
might be the reasons for the different diagnostic
value of CRP and sTREM-1. In the analysis of prog-
nostic value, although higher serum CRP level was
observed in the non-survivors in univariate analy-
sis, this effect was not seen in multivariate analy-
sis (Table 3). It could be because the short-term
mortality correlates better with other inflamma-
tory variables, such as the level of serum cytokines
or sTREM-1, than with the serum CRP level.
There were several limitations in the present
study. First, the number of patients was small. 
In the non-septic group, only 13 patients were
enrolled. Based on our data for post hoc power
analysis, a clinical trial to clarify the diagnostic
value of serum sTREM-1 levels for infection is 
estimated to require 545 patients in each group
under a statistical power of 80% and a signifi-
cance criterion of 5%. Second, we did not analyze
other inflammatory markers, such as procalcitonin
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or IL-6. We checked the CRP at day 1, but we did
not follow it up during the course of ARDS. Third,
we did not investigate the presence of peptic ulcer
disease by using pan-endoscopy due to ethical sen-
sitivities for the critical patients who did not pres-
ent with active gastrointestinal bleeding. Peptic
ulcer disease could potentially elevate sTREM-1
levels.37,38 Finally, but not least, the non-septic
ARDS group in our study was defined by a retro-
spective review, which could have compromised
our conclusion about the diagnostic value of
sTREM-1 for sepsis, because of possible occult in-
fections in the group that could not be ruled out.
Clinically, precise prospective identification of
non-septic ARDS is very difficult, because sepsis
is always considered to be the causative differen-
tial diagnosis that is lethal if no adequate treatment
is taken. Large studies, including the detection of
other inflammatory markers, are warranted to
confirm our results.
In summary, the serum sTREM-1 level might
not be a reliable marker to differentiate septic from
non-septic ARDS patients but, as an inflamma-
tory marker, it could provide a useful predictor
of short-term mortality, especially when follow-
up levels have increased in the first 5 days. A de-
cline in serum sTREM-1 levels during treatment
indicates improvement. On the contrary, persis-
tent elevation of serum levels should lead to 
a re-evaluation of treatment management.
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